Benzinga | Mar 1, 2021 09:07AM EST

OncoSec Highlights Publication Of Research In 'Clinical Cancer Research Journal' Demonstrating Ability Of Co.'s TAVO To 'activate tumor antigen specific antitumor immunity in patients with triple negative breast cancer'

PENNINGTON, N.J. and SAN DIEGO, March 1, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced the publication of research demonstrating the ability of its lead candidate TAVO(tm) (tavokinogene telseplasmid), a DNA-based interleukin-12 (IL-12), to activate tumor antigen specific antitumor immunity in patients with triple negative breast cancer (TNBC) in the peer-reviewed medical journal Clinical Cancer Research, a journal of the American Association for Cancer Research. The manuscript by Melinda L. Telli, M.D. et al. is titled, "Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy," and is available online.